Why Blinding Is So Important In Psychedelic Research

Psychedelic research often attracts attention because of the size of the reported clinical effects. But before asking whether those effects are impressive, a more basic methodological question has to be answered: how much confidence should we place in the trial design itself? That is where blinding becomes central. A new systematic review in JAMA Psychiatry argues that functional unblinding is widespread in psychedelic randomized clinical trials and that this creates a serious interpretive problem for the field.

Introduction

In a randomized trial, blinding means that participants, and ideally the people rating outcomes, do not know who received the active treatment and who received placebo or another control. The point is simple. If people know what they received, expectations can begin to shape what they report, how they behave, and even how clinicians interpret improvement. In psychiatry, where many outcomes depend partly on symptom ratings and subjective experience, that protection matters a great deal.

Psychedelic trials have a particular difficulty here. Many of these drugs produce obvious acute psychoactive effects. A participant who has intense perceptual changes, altered sense of time, or a clearly unusual internal state may correctly guess that they received the active drug. Once that happens, the study may remain formally blinded on paper but not in practice. This is what researchers mean by functional unblinding. The review defines it as a situation in which participants or raters correctly identify treatment assignment based on subjective effects, potentially biasing outcomes through expectancy.

What Blinding Actually Does

Blinding is not a technical ornament added to make a trial look rigorous. It is one of the mechanisms that protects the credibility of the result. If a person expects a treatment to help, that expectation itself can influence symptom scores, especially in disorders where mood, anxiety, distress, and meaning-making are central parts of the outcome. The same applies to raters. If they think a participant received the active intervention, their judgments may shift, even unintentionally.

That does not mean every positive result in a psychedelic trial is false. It means the result is harder to interpret when blinding breaks down. A large improvement could reflect a true pharmacologic effect, an expectancy-driven response, or some mixture of the two. If the trial does not assess whether blinding held, it becomes harder to know how much weight to place on the efficacy estimate. The review’s authors argue that this matters not only scientifically but also for regulatory acceptance, because weak blinding challenges the validity of the effect being measured.

Why Psychedelic Trials Face A Special Problem

The review examined randomized clinical trials of psychedelics used as psychiatric interventions. Across 112 trials identified, only 29.5% assessed blinding integrity at all. At the same time, 57.1% of trials mentioned blinding as a limitation. That combination is telling. Many researchers recognized the issue, but far fewer actually measured it.

Where blinding was assessed, the degree of failure was often substantial. The review reports that psilocybin, LSD, and ayahuasca studies frequently showed blinding failure values above 90% among participants and raters. In inert placebo-controlled MDMA trials, blinding failure exceeded 85%. Ketamine trials assessed blinding less often, only 17.9% of the time, though the review notes that blinding appeared better preserved when midazolam was used as a control rather than saline. No control strategy consistently achieved ideal blinding across the literature reviewed.

This is where the paper becomes especially important. The issue is not whether psychedelic researchers are careless. The issue is that these interventions are methodologically difficult to study because their acute effects are hard to hide. That problem becomes even more serious in a field where expectations are unusually strong. Psychedelics are surrounded by media attention, therapeutic hope, and often highly memorable subjective experiences. All of that can amplify expectancy effects, which makes the quality of blinding even more important, not less.

What Readers Should Take From This

The most important takeaway is a restrained one. Weak blinding does not prove that psychedelic therapies do not work. It does mean that some published efficacy estimates may be less secure than they appear. A trial is more persuasive when it can show not only that symptoms improved, but also that the design successfully controlled for expectancy and guessable treatment assignment. That is why the review calls for standardized and validated methods to assess blinding and for improved trial designs that can better separate genuine pharmacologic effects from expectancy-driven responses. In other words, better blinding assessment would not weaken the field. It would strengthen it. If future results remain positive under more credible masking conditions, the evidence base becomes much harder to dismiss. If some effects become smaller, that would still be valuable knowledge, because it would clarify what the treatment is actually doing.

So, the real lesson is methodological rather than ideological. Blinding is not a side issue in psychedelic research. It is part of the evidence itself. When functional unblinding is pervasive, credibility depends not only on the size of the result, but on whether the trial can show that the result survived a fair test.

References

Orsini, D. K., Wong, S., Di Luch, S., Chan, B., Vasudeva, S., Lovell, G. F. M., Le, G. H., Jones, B. D. M., Chisamore, N., Mollica, A., Johnson, D. E., Kaczmarek, E. S., Goel, A., Burke, M. J., Mansur, R., McIntyre, R. S., Husain, M. I., & Rosenblat, J. D. (2026). Blinding integrity in psychedelic randomized clinical trials: A systematic review. JAMA Psychiatry. Advance online publication. https://doi.org/10.1001/jamapsychiatry.2026.0255